Literature DB >> 25312894

Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea.

Inderjote Grewal1, Omar Khan2, William Davis2.   

Abstract

Pansclerotic morphea is a rare subtype of localised scleroderma. Very few cases have been reported in the literature. This case discusses a young man with a 15-year history of pansclerotic morphea, illustrating the clinical course and complications of this disease. Notably, recurrent squamous cell carcinomas with several high-risk features and frequent cellulitis were the basis of many admissions. As often seen with this disease, autoimmune markers were negative. However, marked eosinophilia was noted late in the course. Furthermore, this disease is quite resistant to treatment. Immunosuppressive therapy thus far has perhaps slowed the progression, although not cured the disease in this patient. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 25312894      PMCID: PMC4194986          DOI: 10.1136/bcr-2014-205737

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association.

Authors:  S Singh; L Kumar; B D Radotra
Journal:  Rheumatol Int       Date:  2002-01       Impact factor: 2.631

Review 2.  Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma.

Authors:  Uwe Wollina; Michael Buslau; Birgit Heinig; Ivailo Petrov; Eleonore Unger; Eugenia Kyriopoulou; André Koch; Erich Köstler; Jaqueline Schönlebe; Gunther Haroske; Thorsten Doede; Kyrill Pramatarov
Journal:  Int J Low Extrem Wounds       Date:  2007-12       Impact factor: 2.057

3.  Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children.

Authors:  Rosa Roldan; Guadalupe Morote; Maria del Carmen Castro; Maria Dolores Miranda; Jose Carlos Moreno; Eduardo Collantes
Journal:  J Rheumatol       Date:  2006-12       Impact factor: 4.666

4.  Disabling pansclerotic morphea: clinical presentation in two adults.

Authors:  Sherry Henderson Maragh; Mark D P Davis; Alison J Bruce; Audrey M Nelson
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

5.  Disabling pansclerotic morphea of children.

Authors:  J L Diaz-Perez; S M Connolly; R K Winkelmann
Journal:  Arch Dermatol       Date:  1980-02

Review 6.  Diagnostic complexities of eosinophilia.

Authors:  Nathan D Montgomery; Cherie H Dunphy; Micah Mooberry; Andrew Laramore; Matthew C Foster; Steven I Park; Yuri D Fedoriw
Journal:  Arch Pathol Lab Med       Date:  2013-02       Impact factor: 5.534

7.  Humoral regulation of eosinophilopoiesis in vitro: analysis of the targets of interleukin-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and interleukin-5.

Authors:  Y Sonoda; N Arai; M Ogawa
Journal:  Leukemia       Date:  1989-01       Impact factor: 11.528

  7 in total
  4 in total

1.  Recent Publications by Ochsner Authors.

Authors: 
Journal:  Ochsner J       Date:  2015

2.  Morphea in two patients after being infected to and being vaccinated against SARS-CoV-2 infection.

Authors:  Zeinab Aryanian; Kamran Balighi; Parvaneh Hatami; Nasim Mazloumi Tootoonchi; Azadeh Goodarzi; Zeinab Mohseni Afshar
Journal:  Clin Case Rep       Date:  2022-04-18

Review 3.  Systemic Sclerosis and Malignancy: A Review of Current Data.

Authors:  Nabil Zeineddine; Lara El Khoury; Joseph Mosak
Journal:  J Clin Med Res       Date:  2016-07-30

Review 4.  Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.

Authors:  Alexandre Thibault Jacques Maria; Léo Partouche; Radjiv Goulabchand; Sophie Rivière; Pauline Rozier; Céline Bourgier; Alain Le Quellec; Jacques Morel; Danièle Noël; Philippe Guilpain
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.